Cargando…

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer

BACKGROUND: Control of DNA damage is frequently deregulated in solid tumors. Upregulation of genes within this process can be indicative of a more aggressive phenotype and linked with worse outcome. In the present article we identify DNA damage related genes associated with worse outcome in breast c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nieto-Jiménez, Cristina, Alcaraz-Sanabria, Ana, Páez, Raquel, Pérez-Peña, Javier, Corrales-Sánchez, Verónica, Pandiella, Atanasio, Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609884/ https://www.ncbi.nlm.nih.gov/pubmed/28968952 http://dx.doi.org/10.18632/oncotarget.10886

Ejemplares similares

Mapping Bromodomains in breast cancer and association with clinical outcome
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases
por: Ocaña, Alberto, et al.
Publicado: (2016)

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors
por: Pérez-Peña, Javier, et al.
Publicado: (2017)

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
por: Nieto-Jimenez, Cristina, et al.
Publicado: (2020)

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers
por: Perez-Peña, Javier, et al.
Publicado: (2017)

Transcriptome evolution from breast epithelial cells to basal-like tumors
por: Santpere, Gabriel, et al.
Publicado: (2017)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

Genomic Correlates of DNA Damage in Breast Cancer Subtypes
por: Cabañas Morafraile, Esther, et al.
Publicado: (2021)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Personalized therapies in the cancer "omics" era
por: Ocaña, Alberto, et al.
Publicado: (2010)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022)

Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2022)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
por: Noblejas-López, María del Mar, et al.
Publicado: (2018)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Breast Cancer Heterogeneity and Response to Novel Therapeutics
por: Baliu-Piqué, Mariona, et al.
Publicado: (2020)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
por: Morcillo-Garcia, Sara, et al.
Publicado: (2019)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2020)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors
por: Serrano-Heras, Gemma, et al.
Publicado: (2015)

Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin
por: Pérez-Peña, Javier, et al.
Publicado: (2019)

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
por: Montero, Juan Carlos, et al.
Publicado: (2022)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer
por: Martínez‐Canales, Sandra, et al.
Publicado: (2018)

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
por: Ocana, Alberto, et al.
Publicado: (2014)

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
por: Pandiella, Atanasio, et al.
Publicado: (2015)

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
por: Orive‐Ramos, Ana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lqv0ke832fltlv7k5d5gncqhvq